Table 1

Cytogenetic risk categories in 200 patients with primary myelofibrosis

Patient groupNo. of patients (median survival, mo)Cytogenetic risk groupMedian survival, mo*
All patients 200 (74)    
Sole del(20q) 21 (112)    
Sole del(13q) 8 (105) Favorable  
Sole +9 6 (not reached)  113 
Normal 117 (80)  Normal  
Other abnormalities     
    Sole −5/del(5q) 1 (not reached)    
    Sole −7/7q− 2 (56)   
    20q− plus one other abnormality    
    13q− plus one other abnormality 2 (58)   
    +9 plus one other abnormality 1 (22) Others 46 
    +8 plus one other abnormality 1 (4)   
    Others with 2 abnormalities 7 (29)   
    Others with sole abnormalities 11 (46)   
Complex karyotype 13 (34)  Unfavorable  
Sole +8 7 (28)  34 
Patient groupNo. of patients (median survival, mo)Cytogenetic risk groupMedian survival, mo*
All patients 200 (74)    
Sole del(20q) 21 (112)    
Sole del(13q) 8 (105) Favorable  
Sole +9 6 (not reached)  113 
Normal 117 (80)  Normal  
Other abnormalities     
    Sole −5/del(5q) 1 (not reached)    
    Sole −7/7q− 2 (56)   
    20q− plus one other abnormality    
    13q− plus one other abnormality 2 (58)   
    +9 plus one other abnormality 1 (22) Others 46 
    +8 plus one other abnormality 1 (4)   
    Others with 2 abnormalities 7 (29)   
    Others with sole abnormalities 11 (46)   
Complex karyotype 13 (34)  Unfavorable  
Sole +8 7 (28)  34 
*

P = .003, favorable versus normal versus other abnormalities versus unfavorable.

47,XY,t(1;9)(p10;q10),+der(1;9)(q10;p10)[14]/46,XY[6]; 46,XY,t(2;11)(p15;q23)?c[17]/46,idem,del(5)(q13q33)[3]; 46,XX,−7,+r[18]/46,XX[2]; 46,XX,−20,+mar[20]; 46,XY, 8p−,9q+; +8 and del(20q−); +1,der(1;13)[2].

+19; 47,XY,+21[20]; 1q+; 46,XY,i(17q)[7]/46,XY[13]; 46,XY,inv(3)(q21q26.2)[12]; 46,XY,+1,der(1;7)(q10;p10)[7]/46,XY[13]; 46,XX,+1,der(1;7)(q10;p10)[8]/46,XX[2]; 46,XY,t(2;12)(p13;q13)?c[20]; 46,XY,add(2)(p13)[6]46,idem,+9,−21[1]/46,XY[13]; add(20)(q13.3); 46,XX,add(9)(q13)[2]/46,XX[28].

Close Modal

or Create an Account

Close Modal
Close Modal